Key takeaway: Shalby Limited submitted an investor presentation detailing its financial and operational performance for the quarter ended June 30, 2026. The presentation highlighted consolidated total revenue of ₹3,386 million, an increase from ₹3,034 million in the same quarter of the previous year. Consolidated EBITDA was reported at ₹490 million, slightly up from ₹485 million year-over-year. However, consolidated profit before tax (PBT) decreased to ₹197 million from ₹227 million, while consolidated profit after tax (PAT) rose to ₹105 million compared to ₹77 million in Q1 FY26. The standalone performance showed total revenue of ₹2,591 million, up from ₹2,422 million, but EBITDA and PBT declined. The presentation also outlined operational metrics, including a 6.2% increase in inpatient count and a 3.5% rise in surgeries performed. Management emphasized ongoing growth and diversification in various medical specialties.

Key takeaway: Shalby Limited's earnings conference call on May 29, 2026, highlighted a strong financial performance for Q4 FY2026, with consolidated revenue increasing by 9.4% year-on-year to INR295.5 crores. EBITDA rose significantly by 43.1% to INR37.4 crores, resulting in an EBITDA margin of 12.7%. The company reported a consolidated profit before tax (PBT) of INR9.6 crores, compared to a loss in the previous year, and a consolidated profit after tax (PAT) of INR18.5 crores. For the full fiscal year, consolidated revenue grew by 4.8% to INR1,168.2 crores, with a PAT of INR34.7 crores, a substantial increase from the previous year. Management noted ongoing improvements in operational efficiency and profitability, particularly in the MedTech segment, which saw a revenue increase of 45% in Q4. The call also addressed challenges in international operations due to geopolitical issues but expressed confidence in recovery and growth in other markets.

Key takeaway: Shalby Limited held its Q3 FY '26 earnings conference call on February 12, 2026, where management discussed the company's financial performance. Consolidated revenue for the quarter was reported at INR 279.4 crores, a slight decrease of 0.6% year-on-year. The consolidated EBITDA was INR 37.5 crores, with a margin of 13.4%, down from 14% in the previous year. The consolidated profit before tax (PBT) also declined to INR 9.2 crores, while the profit after tax (PAT) improved to INR 1.3 crores, compared to a loss in the same quarter last year. The standalone hospital business saw a revenue drop of 2.6% year-on-year, with a PAT of INR 13.8 crores. Management highlighted a focus on clinical excellence, successful surgeries, and the nurturing of talent through the Shalby Academy. The MedTech segment reported a significant revenue increase of 29% year-on-year, driven by strong domestic execution and international expansion efforts. The call concluded with a Q&A session addressing various operational challenges and strategic initiatives.

Key takeaway: Shalby Limited submitted an investor presentation detailing its financial and operational performance for the quarter ended December 31, 2025. The presentation highlighted consolidated revenue of ₹2,794 million, a slight decrease from ₹2,811 million in the same quarter of the previous year. Consolidated EBITDA was reported at ₹375 million, down from ₹393 million year-over-year. The company also noted a consolidated profit before tax (PBT) of ₹92 million, compared to ₹124 million in Q3 FY25. Standalone revenue was ₹2,210 million, with EBITDA at ₹354 million, both showing declines from the previous year. The presentation included insights into the company's hospital business, implant business, and strategic growth initiatives, emphasizing advancements in technology and clinical excellence. Management expressed a commitment to maintaining high standards in patient care and operational efficiency.